Luteolin for neurodegenerative diseases: a review
Pharmacological Reports · 2024-08 · 76 (4) · 644-664
DOI: 10.1007/s43440-024-00610-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Reports, online erschienen am 21.06.2024. Verfasst von Dunuvilla Kavindi Jayawickreme und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, Lublin, 20-033, PL, Poland. Hauptthemen laut MEDLINE: Luteolin, Neurodegenerative Diseases, Neuroprotective Agents. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and multiple sclerosis affect millions of people around the world. In addition to age, which is a key factor contributing to the development of all neurodegenerative diseases, genetic and environmental components are also important risk factors. Current methods of treating neurodegenerative diseases are mostly symptomatic and do not eliminate the cause of the disease. Many studies focus on searching for natural substances with neuroprotective properties that could be used as an adjuvant therapy in the inhibition of the neurodegeneration process. These compounds include flavonoids, such as luteolin, showing significant anti-inflammatory, antioxidant, and neuroprotective activity. Increasing evidence suggests that luteolin may confer protection against neurodegeneration. In this review, we summarize the scientific reports from preclinical in vitro and in vivo studies regarding the beneficial effects of luteolin in neurodegenerative diseases. Luteolin was studied most extensively in various models of Alzheimer’s disease but there are also several reports showing its neuroprotective effects in models of Parkinson’s disease. Though very limited, studies on possible protective effects of luteolin against Huntington’s disease and multiple sclerosis are also discussed here. Overall, although preclinical studies show the potential benefits of luteolin in neurodegenerative disorders, clinical evidence on its therapeutic efficacy is still deficient. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Akademicka 19, Lublin, 20-033, PL, Poland.
- Department of Experimental Pharmacology, Institute of Rural Health, Jaczewskiego 2, Lublin, 20-950, Poland.
- Department of Animal Physiology and Pharmacology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Akademicka 19, Lublin, 20-033, PL, Poland.
- Department of Animal Physiology and Pharmacology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Akademicka 19, Lublin, 20-033, PL, Poland. katarzyna.socala@mail.umcs.pl.
Zitieren
APA
Jayawickreme, D. K., Ekwosi, C., Anand, A., Andres-Mach, M., Wlaź, P., & Socała, K. (2024). Luteolin for neurodegenerative diseases: a review. Pharmacological Reports, 76(4), 644-664. https://doi.org/10.1007/s43440-024-00610-8
Vancouver
Jayawickreme DK, Ekwosi C, Anand A, Andres-Mach M, Wlaź P, Socała K. Luteolin for neurodegenerative diseases: a review. Pharmacological Reports. 2024;76(4):644-664. doi:10.1007/s43440-024-00610-8
BibTeX
@article{Jayawickreme2024,
author = {Jayawickreme, Dunuvilla Kavindi and Ekwosi, Cletus and Anand, Apurva and Andres-Mach, Marta and Wlaź, Piotr and Socała, Katarzyna},
title = {Luteolin for neurodegenerative diseases: a review},
journal = {Pharmacological Reports},
year = {2024},
volume = {76},
number = {4},
pages = {644--664},
doi = {10.1007/s43440-024-00610-8}
}
EUVIMED